Dispensed: Pharma middlemen get their day in the hot seat, life at Flatiron Health a year after acquisition, and almost $1 billion invested in clinical trial startups
|04/12/2019||Posted by BusinessMediaguide.Com under General World News||
Well, it’s official: Bristol-Myers Squibb and Celgene are likely going to form the megamerger of their dreams, after shareholders approved the $74 billion union.
Before heading into the weekend on that note, I wanted to leave you with a recap of all the news that kept Business Insider’s healthcare team busy this week (tune in next week for some big pieces we’ve been working on for a while!).
We kept a close eye on Capitol Hill this week, where pharmacy benefit managers and drugmakers alike faced lines of questioning from Congress.
Here’s a recap of what all went down in read more >>>